Citations

Clear

6413 citation(s) found for "Su, Christopher".

Intra‐Articular Purified Exosome Product and Hyaluronan Attenuate Osteoarthritis Progression in a Minimally Invasive Turkey Model
Lei, Xing , Wang, Lei, Reisdorf, Ramona L., Brosig, Maggie A, Moran, Steven L, Evans, CH, Zhao, Chunfeng, Brosig, Maggie, Moran, Steven L., Evans, Christopher H., Zhao, Chunfeng

Mayo Clinic

Journal of Orthopaedic Research | April 29, 2026 | Volume: 44 | Issue: 5 | Pages: No page available

10.1002/jor.70207 | PMID 42051070 Get It

ABSTRACT Our study aimed to develop a novel, reproducible, minimally invasive turkey knee osteoarthritis (OA) model and evaluate whether intra‐articular hyaluronan (HA) alone or combined with purified exosome product (PEP) attenuates OA‐related functional and structural deterioration. OA was induced arthroscopically by transection of the anterior and posterior cruciate ligaments with resection of the anterior horn of the medial meniscus. Animals received intra‐articular injections of saline, HA, or PEP + HA at postoperative 2–5 weeks. Gait was assessed at 4, 8, and 12 weeks, and cartilage degeneration, subchondral bone sclerosis, osteophyte formation, synovial fibrosis, heterotopic ossification, and meniscal integrity were evaluated by quantitative CT and histology at week 12. Compared with saline, HA improved lameness, preserved cartilage glycosaminoglycan content, and reduced meniscal rupture, subchondral bone sclerosis, and periarticular heterotopic ossification. PEP + HA provided additional benefits, including prolonged stance phase, reduced synovial fibrosis, and greater chondroprotection than HA alone, while plantar pressure variables, subchondral bone remodeling, and patellar osteophytes did not differ between HA and PEP + HA. This turkey model reliably produces human‐like OA changes and enables longitudinal functional and structural assessment. Intra‐articular HA mitigated OA progression, and the addition of PEP conferred incremental joint protection.
Lead Extraction and Outcomes in Frail Patients With Cardiac Implantable Electronic Device Infections in the United States
Bharadiya, Vishwesh , Agarwal, Siddharth, Analuisa, Karol Quelal, Patil, Shivaraj , Mainigi, Naiya, Munir, Muhammad Bilal , DeSimone, Christopher V. , Deshmukh, Abhishek J., Agarwal, Siddharth , Quelal, Karol , Bharadiya, Vishwesh , Quelal, Karol , Patil, Shivaraj P, Munir, Muhammad Bilal , DeSimone, Christopher V , Agarwal, Siddharth , Asad, Zain Ul Abideen , DeSimone, Daniel C. , Deshmukh, Abhishek

Mayo Clinic

Journal of Cardiovascular Electrophysiology | April 27, 2026 | Volume: 37 | Issue: 7 | Pages: 1588-1591

10.1111/jce.70347 | PMID 42037139 Get It

ABSTRACT Introduction Frailty is increasingly recognized as an important determinant of outcomes in cardiovascular disease, yet its population‐level impact among patients hospitalized with cardiac implantable electronic device (CIED) infections remains incompletely defined. We examined the prevalence of frailty and its association with clinical outcomes and utilization of transvenous lead removal (TLR) in a contemporary national cohort. Methods and Results We analyzed the National Readmissions Database from 2016–2021 to identify adults hospitalized for CIED infections. Frailty was defined using the Johns Hopkins adjusted clinical groups frailty‐defining diagnoses. Of 288,402 patients hospitalized with CIED infections, 25.1% were classified as frail. Frail patients experienced significantly higher in‐hospital mortality (10.8% vs. 4.6%), 30‐day mortality (9.2% vs. 5.5%), complications, longer length of stay, lower rates of discharge home, and higher 30‐day readmissions compared with non‐frail patients (all p < 0.01). TLR was performed less frequently in frail patients (10.8% vs. 13.4%; adjusted odds ratio [aOR] 0.80, 95% CI 0.76–0.83). On adjusted analyses, TLR was independently associated with lower in‐hospital mortality, 30‐day mortality, and 30‐day readmissions in both frail and non‐frail patients. Conclusion Among patients hospitalized with CIED infections, TLR was independently associated with lower mortality and readmissions in both frail and non‐frail patients, despite lower utilization in frail individuals. Frailty was common (25.1%) and independently associated with significantly worse outcomes. These findings highlight important associations between frailty, treatment patterns, and outcomes that warrant prospective evaluation.
Phosphorylated ubiquitin is a secondary messenger and an epigenetic mark mediating mitochondria to nucleus signaling
Mercer, Thomas J., Dániel, Bence , Fredrickson, Craig, Le, Daniel , Lee, Serena, Kulkarni, Vineet Vinay , Hou, Xu , Ngu, Hai , Jung, Min, Heon‐Roberts, Rachel , Smith, Amelia, Cheung, Tommy K. , Gastaldo, Denise , Jeong, Claire G. , Foreman, Oded , Bingöl, Bariş , Fiesel, Fabienne C , Ryan, Brent J , Dickson, Dennis W , Fiesel, Fabienne C. , Kameswaran, Vasumathi , Dickson, Dennis W. , Springer, Wolfdieter , Rose, Christopher M.

Mayo Clinic

No container title available | April 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.24.719390 | PMID 42079170 Get It

Abstract Parkinson’s disease (PD) is commonly associated with dysfunctional mitochondrial homeostasis. PINK1, a S/T kinase mutated in early-onset PD, generates phosphoserine 65 ubiquitin (pS65Ub) on damaged mitochondria facilitating their removal. Here, we show that pS65Ub translocates into the nucleus after generation at damaged mitochondria and is directly attached to substrates by resident E3 ligases. Histone H2A is a major substrate and is modified at lysine 119 (H2AK119) by the polycomb silencer, E3 ligase RING1B. At nucleosomes, pS65Ub simultaneously suppresses RING1B and potentiates H2A deubiquitinases USP16 and USP21. Epigenetic profiling and RNA sequencing reveal that pS65Ub is enriched at the promoters of poorly expressed yet dynamically regulated genes and is associated with H2AK119ub depletion. Functionally, we show that pS65Ub enrichment drives polycomb target gene expression, which accelerates the maturation of dopaminergic neurons. Importantly, post-mortem PD brains exhibit elevated nuclear pS65Ub, potentially linking nuclear pS65Ub accumulation with disease pathogenesis. Together, these data indicate that pS65Ub generated at damaged mitochondria regulates fundamental cellular processes at distant sites.
Multi‐Factorial and Multi‐Component Fall Prevention Interventions Initiated From the Emergency Department: A Systemic Review and Meta‐Analysis
Mowbray, Fabrice I., Tarnovsky, Ian A., Lee, Sangil, Ryer, Suzanne , Maddow, Charles L., Carpenter, Christopher R. , Malsch, Aaron , Ragsdale, Luna , Liu, S X, Mowbray, Fabrice , Southerland, Lauren T , Mowbray, Fabrice , Harper, Kristie , Ryer, Suzanne , Carpenter, Christopher R , Malsch, Aaron J , Liu, Shan W , Southerland, Lauren T. , Tarnovsky, Ian, Lo, Alexander X.

Mayo Clinic

Academic Emergency Medicine | April 25, 2026 | Volume: 33 | Issue: 4 | Pages: No page available

10.1111/acem.70245 | PMID 42032852 Get It

ABSTRACT Background Fall risk screening and prevention interventions initiated from the Emergency Department (ED) are endorsed by current national guidelines. We aimed to evaluate the effectiveness of ED‐based multi‐factorial and multi‐component interventions to prevent falls. Methods We conducted a systematic review and meta‐analysis of interventions for fall prevention initiated in the ED for older patients (age ≥ 60 years). Multi‐component and multi‐factorial interventions were included. We excluded studies without a control or comparison group. The published literature was searched from 2019 to May 2024. Risk of bias was assessed with the Newcastle Ottawa tool for observation studies and the Cochrane Risk of Bias v2 for randomized trials. A meta‐analysis was completed for the outcomes with multiple studies. Results The search resulted in 6312 abstracts with 2571 duplicates, for 3741 unique citations. A total of 18 studies were included in the systematic review; 5 were rated as high risk of bias/low quality. The articles were heterogenous in the intervention type (8 multi‐factorial and 8 multi‐component), setting (ED focused vs. outpatient), intervention components (i.e., nurses, physicians, therapists), and size (103–1435 participants). The interventions did not decrease risk of falls at 3 months (risk difference 0.05 95% CI [0.00; 0.09]), 6 months (0.07 [−0.04; 0.18]) or 12 months (−0.02 [−0.11; 0.07]). ED revisits at 1 month (−0.01 [−0.03; 0.00]), 3 months (−0.04 [−0.14; 0.06]), and 12 months (0.02 [−0.05; 0.25]) were also unchanged. Mortality and hospitalization rates were also unaffected. Improvement in functional status was noted in 4 of 5 studies reporting this outcome. Conclusions Multi‐factorial and multi‐component fall prevention interventions initiated from the ED did not decrease falls or recurrent healthcare use. These interventions may improve functional status in older adults at fall risk. Comparisons are limited by the heterogeneity in types of interventions, intervention compliance, and timing of outcomes.
Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy
Eliashiv, Dawn , Rao, Vikram R. , Jobst, Barbara C. , Szaflarski, Jerzy P. , Rolston, John D., Kaye, Lesley , Bullinger, Katie L. , Dugan, Patricia , Burdette, David E. , Peters, Angela , Sheikh, Atif, Haas, Kevin F., Mnatsakanyan, Lilit , Bensalem‐Owen, Meriem, Study, for the RNS System PAS, Doherty, Michael J., Razavi, Babak, Fisher, Tiffany , Modur, Pradeep N., Constantino, Tawnya, Salanova, Vicenta , Taraschenko, Olga , Rivera‐Cruz, Angélica , Balabanov, Antoaneta, Aboumatar, Sami, Fried, Itzhak , Drees, Cornelia , Shin, Hae Won, Jaisani, Zeenat , Maciver, Stephanie , Patra, Sanjay , Chang, Edward F. , Gwinn, Ryder, Stoub, Travis , Crabtree, Tami , Seale, Cairn G. , McFadden, Sharon C. , Norman, Jacob F. , Johnson, Lise, Elisevich, Kort, Peng, Emory, Mazumder, Rajashi, Jennings, Tara, Esparza, Melissa Johnston, Harid, Nitish, Farooque, Pue , Hirsch, Lawrence, Gerrard, Jason, Wabulya, Angela , Riley, Kristen, Pati, Sandipan, Johnson, Jessica, Kirchoffer, Kaitlyn, Bamps, Yvan , Rolston, John D. , Rolston, John D , Kaye, Lesley C , Ganguly, Taneeta Mindy , Bullinger, Katie , Dugan, Patricia C , Burdette, David E , Peters, Angela Y , Sheikh, Atif , Haas, Kevin F , Nair, Dileep R , Mnatsakanyan, Lilit , Quraishi, Imran H , Bensalem-Owen, Meriem K , Doherty, Michael J , Razavi, Babak , Fisher, Tiffany L. , Skidmore, Christopher , Modur, Pradeep N , Constantino, Tawnya M , Cole, Andrew J , Taraschenko, Olga , Rivera-Cruz, Angelica , Wheless, James W , Tandon, Nitin , Balabanov, Antoaneta , Aboumatar, Sami , Fried, Itzhak , Drees, Cornelia , Shin, Hae Won , Jaisani, Zeenat , MacIver, Stephanie E , Patra, Sanjay E , Chang, Edward F , Willie, Jon T , Gwinn, Ryder , Stoub, Travis , Stern, John M , Crabtree, Tami , McFadden, Sharon C , Norman, Jacob F , Johnson, Lise , Morrell, Martha J , Jobst, Barbara , Rao, Vikram R , Ganguly, Taneeta M. , Nair, Dileep , Skidmore, Christopher , Cole, Andrew J. , Wheless, James W. , Tandon, Nitin , Gwinn, Ryder P. , Stern, John M. , Morrell, Martha J. , Pellinen, Jacob , Herlopian, Aline , Sivaraju, Adithya , Damisah, Eyiyemisi C. , Gerrard, Jason L. , Bentley, J. Nicole , Pati, Sandipan Bankim Behari

Mayo Clinic

Neurology | April 24, 2026 | Volume: 106 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000214875 | PMID 42030518 Get It

First-in-Human Clinical Experience With Focal Pulsed Field and Radiofrequency Dual-Modality Ablation for Treatment Refractory Left Ventricular Summit PVCs
Patil, Shivaraj, Liu, Xiaoke Ken, Siontis, Konstantinos C. , Prasitlumkum, Narut , Asirvatham, S, Cha, Yong‐Mei , Munoz, Freddy Del‐Carpio , Deshmukh, Abhishek , DeSimone, Christopher V. , Friedman, Paul A. , Madhavan, Malini , Mulpuru, S K, Munger, Thomas, Nguyen, Duy T. , Tan, N, Sugrue, Alan , Killu, Ammar M. , Asirvatham, Samuel J. , Liu, Xiaoke , Asirvatham, Samuel J , Del-Carpio Munoz, Freddy , Deshmukh, Abhishek J , Ezzeddine, Fatima , Friedman, Paul A , Kowlgi, Narayan G , Madhavan, Malini , Mulpuru, Siva K , Nguyen, Duy, Noseworthy, Peter A , Tan, Nicholas , Sugrue, Alan , Kapa, Suraj , Killu, Ammar M , DeSimone, Christopher V , Prasitlumkum, Narut , Ezzeddine, Fatima M. , Kowlgi, Gurukripa N. , Mulpuru, Siva K. , Munger, Thomas M., Noseworthy, Peter A. , Kapa, Suraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 24, 2026 | Volume: 19 | Issue: 6 | Pages: No page available

10.1161/circep.126.014942 | PMID 42030455 Get It

BACKGROUND: Radiofrequency (RF) ablation of premature ventricular complexes (PVCs) originating from the left ventricular summit may be unsuccessful, highlighting the need for alternative approaches. We aimed to assess the efficacy and safety of a novel dual-modality focal catheter in treating left ventricular summit PVCs in patients who had failed previous RF ablation. METHODS: Patients were prospectively enrolled and underwent a redo ablation procedure using an irrigated, contact-force sensing, dual-modality focal catheter (TactiFlex Duo, Abbott) under compassionate use indication. The ablation strategy, including the choice of energy modality (monopolar pulsed field [PF], RF, or both), was left to the operator’s discretion. Safety assessments included serial biomarkers, renal function, and CMR within 36 hours. Efficacy was defined as ≥80% reduction in PVC burden with symptom resolution at 3-month follow-up. RESULTS: Six consecutive patients (4 men; mean age, 53.8±15 years) with symptomatic left ventricular summit PVCs and a prior failed RF ablation (range, 1–2) were prospectively enrolled. All PVCs had an inferior axis, with a left bundle V1 morphology observed in 4 of 6 cases (mean burden, 30.1±5.3%). Acute suppression of PVCs was achieved in all cases. Acute suppression with a single PF application in the great cardiac vein-anterior interventricular vein occurred in 2 patients, while 3 patients required additional RF, PF, or combined RF+PF applications at adjacent sites. One patient with an inaccessible great cardiac vein-anterior interventricular vein was successfully treated in the left ventricular outflow tract with RF+PF application. Transient, reversible left anterior descending vasospasm was observed during PF delivery in 2 of 5 cases that underwent PF application adjacent to a coronary artery, despite pretreatment with intracoronary nitroglycerin without ECG or hemodynamic sequelae. All patients had durable suppression of PVCs at follow-up. CONCLUSIONS: In its first human application, dual-modality ablation was feasible and effective for refractory left ventricular summit PVCs. Transient coronary vasospasm occurred, though it was reversible and without acute clinical consequences.
Systemic Embolic Events in People Who Inject Drugs With Patent Foramen Ovale and Right-Sided Infective Endocarditis: A Systematic Review
Cuervo, Guillermo , Gerberi, Dana , DeSimone, Christopher V, Deshmukh, Abhishek , Miró, José María, Sabbagh, Abdallah El , DeSimone, Daniel C. , Baddour, Larry M. , Miró, José M. , Chesdachai, Supavit , Gerberi, Danielle J , Deshmukh, Abhishek J , Miró, José María , DeSimone, Daniel C , Baddour, Larry , Cuervo, Guillermo , Chesdachai, Supavit , DeSimone, Christopher V.

Mayo Clinic

Open Forum Infectious Diseases | April 24, 2026 | Volume: 13 | Issue: 5 | Pages: No page available

10.1093/ofid/ofag245 | PMID 42169692 Get It

Abstract Background Knowing the prevalence of patent foramen ovale (PFO) and the increasing number of people who inject drugs (PWID) with right-sided infective endocarditis (RSIE), we aimed to better characterize the syndrome of injection drug use, RSIE, and PFO with systemic embolic events. Method A systematic search across multiple databases was independently screened using predefined criteria (from inception until September 2025). Published cases of adult PWID diagnosed with RSIE and ischemic stroke or other systemic embolic event were included, provided they had PFO assessment. Individuals were excluded if they had cardiac implantable electronic device (CIED) infections or any other conditions associated with systemic or paradoxical embolism. Results The review identified 13 studies with 14 young patients, mostly without comorbidities, predominantly infected with Staphylococcus aureus. In most cases, echocardiography revealed large tricuspid valve vegetations. Neuroimaging confirmed multiple ischemic infarcts, while 5 patients showed emboli outside the central nervous system (4 of them as the only systemic embolism). At least 11 (79%) patients had echocardiographic evidence of right-to-left shunting. Management included cardiac surgery in 6 cases that involved valve replacement or repair, percutaneous PFO closure in 2 cases, and percutaneous mechanical aspiration in 1 case. Three patients (21%) died during hospitalization, and only 27.3% patients had outpatient follow-up. Conclusions RSIE with systemic embolism in PWID with PFO has rarely been reported, affects younger patients without sex predominance, and was usually due to S. aureus with large tricuspid vegetations. Right-to-left shunting was characteristic, and outcomes were poor despite combined medical, surgical, and interventional therapies.
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers
Benveniste, Pierre‐Louis , Létourneau‐Guillon, Laurent , Araújo, David , Fetco, Dumitru , Hori, Masaaki , Kamiya, Kouhei , Messina, Steven, Audoin, Bertrand , Blezek, Daniel, Brisset, Jean‐Christophe , Charlson, Erik, Chen, Michelle , Demortière, Sarah , Edan, Gilles , Filippi, M, Kerbrat, Anne , Kirschke, J, Labauge, Pierre, Liu, Yaou, Mainero, Caterina , Medina, Nilser Laines , Reich, Daniel S. , Shepherd, Timothy M. , Smith, Seth A. , Talbott, Jason, Tauhid, Shahamat , Treaba, Constantina A. , Cohen-Adad, Julien, Fetco, Dumitru , Hori, Masaaki , Audoin, Bertrand , Bakshi, Rohit , Bannier, Elise , Blezek, Daniel , Brisset, Jean-Christophe , Callot, Virginie , Chen, Michelle , Ciccarelli, Olga , Edan, Gilles , Filippi, Massimo , Granberg, Tobias , Granziera, Cristina , Hemond, Christopher C , Keegan, B Mark , Kerbrat, Anne , Kirschke, Jan , Kollind, Shannon H , Lee, Lisa Eunyoung , McGinnis, Julian , Laines Medina, Nilser , Mühlau, Mark , Nair, Govind , O'Grady, Kristin P , Oh, Jiwon , Ouellette, Russell , Reich, Daniel S , Rocca, Maria A , Smith, Seth A , Stawiarz, Leszek , Tam, Roger , Traboulsee, Anthony , Treaba, Constantina Andrada , Valsasina, Paola , Yiannakas, Marios , Cohen-Adad, Julien , Guillon, Laurent Letourneau , Chougar, Lydia , Messina, Steven A. , Tsagkas, Charidimos , Blezek, Daniel J. , Ciccarelli, Olga , Filippi, Massimo , Keegan, B. Mark , Labauge, Pierre , Lee, Lisa Eunyoung , Nair, Govind , O’Grady, Kristin P. , Prat, Alexandre , Rocca, Maria A. , Talbott, Jason F. , Tam, Roger , Lombaert, Hervé

Mayo Clinic

Multiple Sclerosis Journal | April 24, 2026 | Volume: 32 | Issue: 6 | Pages: 598-613

10.1177/13524585261427333 | PMID 42028790 Get It

Background/Objectives: Characterizing spinal cord multiple sclerosis (MS) lesions in MRI is critical for diagnosis, monitoring, and treatment evaluation. However, current automated approaches for lesion detection and segmentation are typically designed for specific MRI contrasts or acquisition sites, limiting their generalizability in real-world clinical settings where imaging protocols vary widely. This work proposes a robust multi-site, multi-contrast segmentation framework for spinal cord lesions. Methods: The segmentation model was trained and evaluated on a large-scale dataset comprising 4428 annotated images from 1849 persons with MS across 23 imaging centers, encompassing six MRI contrasts (T1w, T2w, T2*w, PSIR, STIR, and UNIT1) acquired at 1.5 tesla (T), 3 T, and 7 T. Results: Likert-type assessment performed by neuroradiologist ratings demonstrated superior generalization of the model compared to existing contrast-specific pipelines ( p < 0.01). Additional experiments evaluated robustness across spinal levels, acquisition resolutions, binarization thresholds, and quantitative evaluation on external labeled datasets. Conclusions: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher. Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast
A proof‐of‐concept study of multitask learning for cranial synthetic CT generation across heterogeneous MRI field strengths
Xin, Zhuoyao, Zhang, Yiren, Wu, Christopher , Dong, Li , Gu, Chunming , Middlebrooks, Erik H. , Hua, Jun , Guo, Jia, Greco, Elena , Middlebrooks, Erik H , Liu, Dong, Greco, Elena, Hua, Jun

Mayo Clinic

Medical Physics | April 24, 2026 | Volume: 53 | Issue: 5 | Pages: No page available

10.1002/mp.70429 | PMID 42027157 Get It

Abstract Background Accurate synthesis of computed tomography (CT) images from magnetic resonance imaging (MRI) is clinically valuable for cranial applications such as attenuation correction, radiotherapy planning, and image‐guided interventions. However, the heterogeneity of MRI data across magnetic field strengths and pulse sequences limits the generalizability of existing methods, posing a barrier to clinical translation. Purpose This study aims to reformulate cranial CT synthesis as a modular, structurally coupled problem using a deep learning approach, enhancing adaptability across heterogeneous MRI conditions, including different field strengths and sequence protocols. Methods We implemented a cascaded multitask pipeline that jointly models skull segmentation and Hounsfield Unit (HU) regression in anatomically targeted regions. A 3D patch‐based training paradigm shifts the modeling focus from global image translation to localized bone feature extraction. The backbone leverages a residual Mamba‐based state space model within a 3D U‐Net structure to improve spatial representation, while a Transformer U‐Net serves as a widely recognized reference baseline comparison. The model was trained and evaluated in terms of multi‐modal (T1‐weighted and T2‐FLAIR) and cross‐domain transferability from a public 1.5 Tesla brain dataset ( n = 37) to an independent 7 Tesla clinical brain dataset ( n = 44). Performance was assessed using Dice and Jaccard indices for segmentation accuracy and mean absolute error (MAE) for HU regression. Results Quantitative analysis showed that our multitask pipeline, incorporating both morphological and HU map prediction stages, significantly outperformed conventional direct MRI‐to‐CT mapping across all metrics on the public 1.5T dataset (p < 0.05). Consistent performance on an external 7T clinical dataset (p < 0.001) further demonstrated the method's robustness and adaptability across field strengths. Conclusion These findings support that task‐structured training for modality transformation markedly improves both accuracy and generalizability of cranial CT synthesis across heterogeneous MRI conditions. The observed consistency across field strengths validates the robustness of the proposed methodology.
Improving Care by FAster risk-STratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the EmeRgency department (ICare-FASTER): a stepped-wedge cluster randomized trial
Than, Martin , Pickering, John W. , Buchan, Vanessa A, Florkowski, Christopher M , Mills, Nicholas L. , Hamill, Laura , Prystowsky, Jason, Harger, Simon, Reed, Mary, Bayless, Jared, Feberwee, Alexander, Attenburrow, Tamsin, Norman, Timothy, Welfare, Oliver, Heiden, Tamika L., Kavsak, Peter, Jaffe, Allan S. , Apple, Fred S. , Cullen, L, Aldous, Sally, Frampton, Christopher MA, Body, Richard, Lord, Sarah Jane, George, Peter Myles, Devlin, Gerard, Kavsak, Peter A. , Mills, Nicholas L , Than, Martin , Pickering, John W , Joyce, Laura R, Buchan, Vanessa, Florkowski, Christopher M , Hamill, Laura, Prystowsky, Jason, Harger, Simon, Reed, Mary, Bayless, Jared, Feberwee, Alexander, Attenburrow, Tamsin, Norman, Timothy, Welfare, Oliver, Heiden, Tamika, Kavsak, Peter , Jaffe, Allan S. , Apple, Fred S. , Peacock, William Frank , Cullen, Louise , Aldous, Sally, Richards, Arthur M , Lacey, Cameron, Troughton, Richard W , Frampton, Christopher, Body, Rick , Mueller, Christian , Lord, Sarah, George, Peter M, Devlin, Gerard

Mayo Clinic

No container title available | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.21.26351433 Get It

ABSTRACT BACKGROUND Point-of-care (POC) high-sensitivity cardiac troponin (hs-cTn) testing has the potential to expedite decision-making and reduce emergency department (ED) length of stay for patients presenting with possible myocardial infarction (MI) by ensuring that results are consistently available when looked for by clinicians. We assessed the real-life effectiveness and safety of implementing POC hs-cTn testing in the ED. METHODS We conducted a pragmatic, stepped-wedge cluster randomized trial. The control arm was usual care with an accelerated diagnostic pathway utilizing a single-sample rule-out step with a central laboratory hs-cTn assay. The intervention arm used the same pathway with a POC hs-cTnI. The primary effectiveness outcome was ED length of stay assessed using a generalized linear mixed model, and the safety outcome was 30-day MI or cardiac death. RESULTS Six sites participated with 59,980 ED presentations (44,747 individuals, 61±19 years, 49.5% female) from February 2023 to January 2025, in which 31,392 presentations were during the intervention arm. After adjustment for co-variates associated with length of stay, the intervention reduced length of stay by 13% (95% confidence intervals [CI], 9 to 16%. P<0.001), corresponding to a reduction of 47 minutes (95%CI, 33 to 61 minutes) from a mean length of stay in the control arm of 376 minutes. The 30-day MI or cardiac death rate was similar in the control and intervention arms (0.39% and 0.39% respectively, P=0.54). CONCLUSIONS Implementation of whole-blood hs-cTnI testing at the POC into an accelerated diagnostic pathway was safe and reduced length of stay in the ED compared with laboratory testing. (Australia New Zealand Clinical Trials Registry ACTRN12619001189112) Clinical Perspective What is new? Point-of-care troponin assays with good precision have become available and received regulatory approval as high-sensitivity assays. A pragmatic stepped-wedge cluster randomized trial implementing the validated Siemens VTLi high-sensitivity point-of-care assay into 6 emergency departments investigating ∼60,000 patients, was conducted to ascertain if the rapid turnaround time reduced lengths of stay. Introduction of the VTLi high-sensitivity point-of-care assay into clinical pathways reduced emergency department lengths of stay by an average 13% (47 minutes) without compromising safety. What are the clinical implications? Early decision-making using a point-of-care high-sensitivity troponin assay within a structured clinical pathway was safe. Faster turnaround means troponin results are consistently available when clinicians first seek them. This can facilitate earlier decisions and reduce patient length of stay.